Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
September 02, 2025 21:33 ET | Source: Mineralys Therapeutics, Inc. RADNOR, Pa.,…
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and…
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2025 17:00 ET | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, Sept.…
How Sparkvia AI Website Tool Proves Real AI Utility on XRP SPARK Public Sale is Open for Early Investors
VALLETTA, Malta, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sparkvia AI has officially…
CEA Industries (BNC) Appoints Seasoned Global Investments Leader, Dr. Russell Read, as Non-Executive Director
New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- CEA Industries Inc. (Nasdaq:…
Cycurion to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU)…
FIRST PATIENT DOSED IN CITRYLLS PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of…
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
New investors NEA and SR One lead round alongside existing investors OrbiMed,…
Coloplast A/S – Announcement no. 07/2025 – Coloplast announces new financial ambition towards 2030
In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company…
Zhejiang-based GNMI Expands Overseas: Hangzhou Becomes a New Starting Point for the China-German Industrial Synergies
Hangzhou, China, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Against the backdrop of…
